Brief: Brainstorm Cell Therapeutics Says Type A Meeting With FDA Granted For NurOwn
27/12/2022 16:30
Dec 27 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS ANNOUNCES TYPE A MEETING WITH
FDA
GRANTED FOR NUROWN®
* BRAINSTORM CELL THERAPEUTICS INC- TYPE A MEETING HAS BEEN
SCHEDULED TO OCCUR ON JANUARY 11, 2023
Source text for Eikon: ID:nPn5NG3X7a
Further company coverage: BCLI.O
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview